Ligand Pharmaceuticals (LGND) Payables (2010 - 2026)

Ligand Pharmaceuticals' Payables history runs 17 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• In Q1 2026, Payables fell 1.9% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (down 1.9% YoY), while the FY2025 annual figure was $3.2 million, down 38.12% from the prior year.
• Payables came in at $5.3 million for Q1 2026 at Ligand Pharmaceuticals, up from $3.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $19.2 million in Q2 2022 to a low of $1.8 million in Q2 2024.
• A 5-year average of $6.3 million and a median of $5.3 million in 2026 frame the typical range for Payables.
• Across the five-year window, Payables tumbled 84.42% in 2023 and soared 378.75% in 2025, its largest moves.
• Ligand Pharmaceuticals' Payables stood at $5.3 million in 2022, then tumbled by 54.27% to $2.4 million in 2023, then soared by 115.62% to $5.2 million in 2024, then tumbled by 38.12% to $3.2 million in 2025, then jumped by 62.57% to $5.3 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $5.3 million, $3.2 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison